Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics

Oncternal Therapeutics, Inc. (ONCT): $0.43

0.09 (+24.78%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ONCT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#286 of 384

in industry

ONCT Price/Volume Stats

Current price $0.43 52-week high $1.33
Prev. close $0.35 52-week low $0.26
Day low $0.35 Volume 414,600
Day high $0.45 Avg. volume 297,743
50-day MA $0.33 Dividend yield N/A
200-day MA $0.40 Market Cap 25.42M

ONCT Stock Price Chart Interactive Chart >

ONCT Stock Summary

  • For ONCT, its debt to operating expenses ratio is greater than that reported by only 4.54% of US equities we're observing.
  • ONCT's price/sales ratio is 30.6; that's higher than the P/S ratio of 95.73% of US stocks.
  • Revenue growth over the past 12 months for ONCTERNAL THERAPEUTICS INC comes in at -64.85%, a number that bests merely 3.47% of the US stocks we're tracking.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ONCTERNAL THERAPEUTICS INC are HOWL, TRDA, IKNA, KRTX, and FGEN.
  • Visit ONCT's SEC page to see the company's official filings. To visit the company's web site, go to www.oncternal.com.

ONCT Valuation Summary

  • In comparison to the median Healthcare stock, ONCT's price/earnings ratio is 101.88% lower, now standing at -0.5.
  • Over the past 241 months, ONCT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ONCT.

Stock Date P/S P/B P/E EV/EBIT
ONCT 2023-11-20 31.3 0.6 -0.5 -0.1
ONCT 2023-11-17 27.8 0.5 -0.4 -0.1
ONCT 2023-11-16 28.7 0.5 -0.5 -0.1
ONCT 2023-11-15 29.1 0.5 -0.5 -0.1
ONCT 2023-11-14 27.3 0.5 -0.4 -0.1
ONCT 2023-11-13 28.1 0.5 -0.4 -0.1

ONCT Growth Metrics

    Its year over year net cashflow from operations growth rate is now at -50.23%.
  • Its year over year price growth rate is now at -79.82%.
  • Its 5 year price growth rate is now at -92.06%.
ONCT's revenue has moved up $1,875,000 over the prior 67 months.

The table below shows ONCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.875 -34.318 -40.843
2022-06-30 3.621 -28.732 -39.348
2022-03-31 4.313 -29.21 -35.289
2021-12-31 4.315 -26.589 -31.333
2021-09-30 5.347 -23.884 -25.817
2021-06-30 3.804 -22.831 -20.582

ONCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ONCT has a Quality Grade of D, ranking ahead of 14.56% of graded US stocks.
  • ONCT's asset turnover comes in at 0.042 -- ranking 334th of 682 Pharmaceutical Products stocks.
  • CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with ONCT.

The table below shows ONCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 1 6.705
2021-03-31 0.051 1 4.190
2020-12-31 0.075 1 3.387
2020-12-31 0.075 1 3.387
2020-09-30 0.123 1 3.414
2020-06-30 0.119 1 3.551

ONCT Price Target

For more insight on analysts targets of ONCT, see our ONCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.50 Average Broker Recommendation 1.38 (Strong Buy)

Oncternal Therapeutics, Inc. (ONCT) Company Bio


Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.


ONCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCT Latest Social Stream


Loading social stream, please wait...

View Full ONCT Social Stream

Latest ONCT News From Around the Web

Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript

Oncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcript November 9, 2023 Oncternal Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.17 EPS, expectations were $-0.15. Operator: Greetings and welcome to Oncternal Therapeutics third-quarter 2023 financial results conference call. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to […]

Yahoo | November 11, 2023

Oncternal Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial Results

The first patient was dosed in our Phase 1/2 study for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor pathway inhibitorsAdditional patients were treated in our ongoing Phase 1/2 study for ONCT-808, our ROR1-targeting autologous CAR T cell therapy, for the treatment of patients with relapsed or refractory aggressive B-cell lymphoma, including patients that have failed prior CD19 CAR

Yahoo | November 9, 2023

Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2023 financial results after the U.S. financial markets close on Thursday, November 9, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s third quarter financial results. The li

Yahoo | November 2, 2023

Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

SAN DIEGO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) has designated ONCT-534, its novel dual-acting androgen receptor inhibitor (DAARI), as a Fast Track development program for the investigation of the treatment of patients with relapsed or refractory metastatic castration-resistant prostate cancer

Yahoo | October 26, 2023

Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board

SAN DIEGO, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the addition of Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board (SAB). Dr. Smith, along with the other Prostate Cancer SAB members, will help guide Oncternal’s next steps in the clinical development of its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-5

Yahoo | October 25, 2023

Read More 'ONCT' Stories Here

ONCT Price Returns

1-mo 43.38%
3-mo 38.75%
6-mo 28.36%
1-year -59.81%
3-year -93.17%
5-year -95.01%
YTD -57.00%
2022 -55.95%
2021 -53.67%
2020 24.05%
2019 -27.66%
2018 -93.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!